Evidence map›Paper›PMID 35705962›Full record

ReviewJournal of biomedical science2022

The power of heteronemin in cancers.

Kuan Wang, Yi-Fong Chen, Yu-Chen S H Yang, Haw-Ming Huang, Sheng-Yang Lee, Ya-Jung Shih, Zi-Lin Li, Jacqueline Whang-Peng, Hung-Yun Lin, Paul J Davis

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of biomedical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Kuan Wang *Graduate Institute of Nanomedicine and Medical Engineering, College of Medical Engineering, Taipei Medical University, 250 Wuxing Street, Taipei 110, Taipei, 11031, Taiwan.
Yi-Fong Chen *Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan.
Yu-Chen S H YangJoint Biobank, Office of Human Research, Taipei Medical University, Taipei, 11031, Taiwan.
Haw-Ming HuangSchool of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, 11031, Taiwan.
Sheng-Yang LeeSchool of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, 11031, Taiwan.
Ya-Jung ShihGraduate Institute of Nanomedicine and Medical Engineering, College of Medical Engineering, Taipei Medical University, 250 Wuxing Street, Taipei 110, Taipei, 11031, Taiwan.
Zi-Lin LiGraduate Institute of Nanomedicine and Medical Engineering, College of Medical Engineering, Taipei Medical University, 250 Wuxing Street, Taipei 110, Taipei, 11031, Taiwan.
Jacqueline Whang-PengCancer Center, Wan Fang Hospital, Taipei Medical University, No. 111, Section 3, Xinglong Road, Wenshan District, Taipei City, 116, Taipei, 11031, Taiwan. jqwpeng@nhri.edu.tw.
Hung-Yun LinGraduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan. linhy@tmu.edu.tw.ORCID http://orcid.org/0000-0003-2824-6419
Paul J DavisPharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, 12144, USA.
Taipei Medical University · TWAlbany College of Pharmacy and Health Sciences · USTaipei Medical University Hospital · TWWan Fang Hospital · TW

Funding

Ministry of Science and Technology, Taiwan MOST109-2124-M-038-001Ministry of Science and Technology, Taiwan MOST109-2314-B-038-038Ministry of Science and Technology, Taiwan MOST109-2314-B-038-125Ministry of Science and Technology, Taiwan MOST110-2124-M-038-001Ministry of Science and Technology, Taiwan MOST110-2314-B-038-114Ministry of Science and Technology, Taiwan MOST110-2314-B-038-115Ministry of Science and Technology, Taiwan MOST110-2314-B-038-119Ministry of Science and Technology, Taiwan MOST110-2314-B-038-147
6 · The paper itself

Abstract

Heteronemin (Haimian jing) is a sesterterpenoid-type natural marine product that is isolated from sponges and has anticancer properties. It inhibits cancer cell proliferation via different mechanisms, such as reactive oxygen species (ROS) production, cell cycle arrest, apoptosis as well as proliferative gene changes in various types of cancers. Recently, the novel structure and bioactivity evaluation of heteronemin has received extensive attention. Hormones control physiological activities regularly, however, they may also affect several abnormalities such as cancer. L-Thyroxine (T

Indexed as

B7-H1 AntigenNeoplasmsHumansTerpenesThyroid HormonesB7-H1 AntigenheteroneminTerpenesThyroid HormonesAnticancerHeteroneminIntegrin αvβ3Marine sesterterpenoidsSponge

Identifiers

PMID35705962
PMCPMC9202199
OpenAlexW4282977890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.